The events of longer survival with IDH mutations are commonly seen in lower grade gliomas such as oligodendroglioma (94%) and less so in astrocytoma (72%) or mixed tumors (83%) [72,73,74,75,76,77] and is reported as a weak predictor of a long time overall survival in GBMs [78]. The gene discussed is IDH2; the disease is central nervous system cancer.